MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ALMS — Alumis Inc. Common Stock
NasdaqAlumis Inc. Common Stock
$7.21
-0.18(-2.44%)
- O
- 7.40
- H
- 7.48
- L
- 7.15
- V
- 2.13M
⏱️ End-of-day dataAs of Oct 1, 2026
Chart
About ALMS
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJun 28, 2024
Employees239
Stock ExchangeNasdaq
Ticker SymbolALMS
Websitehttps://www.alumis.com
Key Financial Statistics
| Market Cap | $918.99M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $2.76 - $31.35 |
| 52-Week Avg Volume | 1.12M |
| VWAP | $7.26 |
| Transactions | 18,810 |
| Total Recorded Bars | 567 days |